Therapeutic enhancement of protective immunity during experimental leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Divanovic, Senad ^a   Trompette, Aurelien ^a,b   Ashworth, Jamie I ^a   Rao, Marepalli B ^a   Karp, Christopher L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; STIBOGLUCONATE SODIUM; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; BIOLOGICAL PRODUCT; DIPHTHERIA TOXIN; IMMUNOLOGIC FACTOR; INTERLEUKIN 2;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNITY; INTERFERON PRODUCTION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SKIN LEISHMANIASIS; T CELL DEPLETION; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG COMBINATION; HUMAN; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BIOLOGICAL AGENTS; DIPHTHERIA TOXIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TREATMENT OUTCOME;

EID: 80053438103     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001316     Document Type: Article

References (55)

1. Herwaldt BL, (1999) Leishmaniasis. Lancet 354: 1191-1199.
2. Reithinger R, (2008) Leishmaniases' burden of disease: ways forward for getting from speculation to reality. PLoS Negl Trop Dis 2: e285.
3. Karp CL, Neva FA, (1999) Tropical infectious diseases in human immunodeficiency virus-infected patients. Clin Infect Dis 28: 947-963; quiz 964-945.
4. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
5. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
6. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, et al. (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
7. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K, (2009) Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 80: 580-582.
8. Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases 31: 1104-1107.
9. Velez ID, Colmenares LM, Munoz CA, (2009) Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment. Rev Inst Med Trop Sao Paulo 51: 231-236.
10. Maurer M, Dondji B, von Stebut E, (2009) What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Med Microbiol Immunol 198: 137-146.
11. Peters N, Sacks D, (2006) Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 213: 159-179.
12. Reiner SL, Locksley RM, (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.
13. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
14. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
15. Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA, (1989) Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 143: 266-274.
16. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, et al. (1990) Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 171: 115-127.
17. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
18. Kane MM, Mosser DM, (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147.
19. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
20. Anderson CF, Oukka M, Kuchroo VJ, Sacks D, (2007) CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
21. Anderson CF, Stumhofer JS, Hunter CA, Sacks D, (2009) IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 183: 4619-4627.
22. Ji J, Masterson J, Sun J, Soong L, (2005) CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J Immunol 174: 7147-7153.
23. Nagase H, Jones KM, Anderson CF, Noben-Trauth N, (2007) Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility. J Immunol 179: 2435-2444.
24. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
25. Heinzel FP, Rerko RM, Hatam F, Locksley RM, (1993) IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 150: 3924-3931.
26. Okwor I, Liu D, Beverley SM, Uzonna JE, (2009) Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci U S A 106: 13951-13956.
27. Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, et al. (2005) Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 73: 4714-4722.
28. Mendez S, Reckling SK, Piccirillo CA, Sacks D, Belkaid Y, (2004) Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med 200: 201-210.
29. Foss FM, (2000) DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clinical Lymphoma 1: 110-116; discussion 117.
30. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
31. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
32. Woodworth TG, (1993) Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus. Clin Exp Rheumatol 11 (Suppl 8): S177-180.
33. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, et al. (2007) IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192-3201.
34. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, et al. (2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177: 84-91.
35. Bacha P, Forte SE, Perper SJ, Trentham DE, Nichols JC, (1992) Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis. Eur J Immunol 22: 1673-1679.
36. Pacheco-Silva A, Bastos MG, Muggia RA, Pankewycz O, Nichols J, et al. (1992) Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol 22: 697-702.
37. Pandrea I, Gaufin T, Brenchley JM, Gautam R, Monjure C, et al. (2008) Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol 181: 6687-6691.
38. Phillips SM, Bhopale MK, Constantinescu CS, Ciric B, Hilliard B, et al. (2007) Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J Neurol Sci 263: 59-69.
39. Ramadan MA, Gabr NS, Bacha P, Gunzler V, Phillips SM, (1995) Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy. Cell Immunol 166: 217-226.
40. Spath GF, Beverley SM, (2001) A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol 99: 97-103.
41. Suffia I, Reckling SK, Salay G, Belkaid Y, (2005) A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol 174: 5444-5455.
42. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, et al. (2008) FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood 112: 2858-2868.
43. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, et al. (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120: 2723-2733.
44. O'Garra A, Vieira P, (2007) T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7: 425-428.
45. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA, (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28: 582-592.
46. Vaclavkova P, Cao Y, Wu LK, Michalek J, Vitetta ES, (2006) A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro. Bone Marrow Transplant 37: 559-567.
47. Heinzel FP, Rerko RM, Hujer AM, Maier RA Jr, (1998) Increased capacity for interleukin-2 synthesis parallels disease progression in mice infected with Leishmania major. Infect Immun 66: 4537-4540.
48. Mazingue C, Cottrez-Detoeuf F, Louis J, Kweider M, Auriault C, et al. (1989) In vitro and in vivo effects of interleukin 2 on the protozoan parasite leishmania. Eur J Immunol 19: 487-491.
49. Bodas M, Jain N, Awasthi A, Martin S, Penke Loka RK, et al. (2006) Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy. J Immunol 177: 4636-4643.
50. Murray HW, Miralles GD, Stoeckle MY, McDermott DF, (1993) Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 151: 929-938.
51. Malek TR, Bayer AL, (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4: 665-674.
52. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941-5946.
53. Oh U, Blevins G, Griffith C, Richert N, Maric D, et al. (2009) Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 66: 471-479.
54. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, et al. (1993) In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]. J Clin Invest 91: 1644-1648.
55. Shevach EM, (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389-400.